Nurix Therapeutics Inc (NASDAQ: NRIX) — Company Overview, News & Financial Data
Nurix Therapeutics develops small molecule therapies targeting critical areas like oncology, using proprietary platforms.
Nurix Therapeutics Inc
Nurix Therapeutics (NASDAQ:NRIX) focuses on discovering, developing, and commercializing small molecule therapies designed to control the body’s protein levels. Leveraging proprietary platforms to manipulate the ubiquitin-proteasome system, their goal is to advance a pipeline of novel therapies targeting critical areas including oncology, inflammation, and immune disorders. Nurix is committed to pushing the boundaries of medical science to create treatments that improve patient outcomes and address unmet medical needs. Through strategic collaborations and internal research, they aim to harness the power of protein degradation to bring innovative medicines from the lab bench to patients in need.
Snapshot
Operations
Products and/or services of Nurix Therapeutics Inc
- DeTIL-0255, a cell therapy using engineered T cells and tumor-infiltrating lymphocytes for advanced solid tumors.
- NX-2127, an orally bioavailable degrader targeting BTK and IMiDs for B-cell malignancies.
- NX-1607, a CBL-B inhibitor designed to stimulate the immune system against solid tumors.
- NX-5948, a brain-penetrant BTK degrader for B-cell malignancies and autoimmune diseases.
- Research collaboration with Sanofi focusing on developing novel targeted protein degradation therapies.
- Partnership with Gilead Sciences to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs.
Nurix Therapeutics Inc executive team
- Arthur T. SandsCEO, President & Director
- Johannes Van HouteChief Financial Officer
- Gwenn M. HansenChief Scientific Officer
- Christine RingChief Legal Officer, Secretary & Chief Compliance Officer
- John KuriyanFounder & Member of Scientific Advisory Board
- Arthur WeissFounder & Member of Scientific Advisory Board
- Rita KwongSenior Accounting Manager
- Pasit PhiasivongsaChief Technical Officer
- Wesley BurwellChief Human Resources Officer
- Jason KantorChief Business Officer
Latest news about Nurix Therapeutics Inc
Nurix Therapeutics initiates Phase 1b/2 leukemia combination trial
United StatesNurix receives $7 million milestone payment from Pfizer collaboration
United StatesNurix Therapeutics shares drop despite positive leukemia drug data
United StatesNurix Therapeutics and Roche forge $2.3B global collaboration
United StatesNurix Therapeutics advances Bexobrutinib toward Phase 3 following strong Q1
United States
Key financials
Reported results for Nurix Therapeutics Inc, in USD.
- Market cap
- 3B
- Revenue (TTM)
- 701.9M
- P/E ratio
- 11.2
- EPS (diluted, TTM)
- 2.4
- Dividend yield
- —
- Profit margin
- 42.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 84M | -285.7M | -264.5M | |
| 54.5M | -213M | -193.6M | |
| 77M | -155.1M | -143.9M | |
| 38.6M | -183.9M | -166M |